

## **Supporting Information**

# Bicyclic diazepinones as dual ligands of the $\alpha 2\delta-1$ subunit of voltage-gated calcium channels and the norepinephrine transporter.

*José Luis Díaz,<sup>1</sup> Félix Cuevas,<sup>2</sup> Gonzalo Pazos,<sup>2</sup> Paula Álvarez-Bercedo,<sup>2</sup> Ana I. Oliva,<sup>2</sup> M. Ángeles Sarmentero,<sup>2</sup> Daniel Font,<sup>2</sup> Agustín Jiménez-Aquino,<sup>2</sup> María Morón,<sup>2</sup> Adriana Port,<sup>1</sup> Rosalía Pascual,<sup>1</sup> Albert Dordal,<sup>1</sup> Enrique Portillo-Salido,<sup>1</sup> Raquel F. Reinoso,<sup>1</sup> José Miguel Vela<sup>1</sup> and Carmen Almansa.<sup>1\*</sup>*

<sup>1</sup>ESTEVE Pharmaceuticals, Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.

Current affiliation: WELAB, Parc Científic Barcelona, C/ Baldiri Reixac 4-8, 08028 Barcelona, Spain.





<sup>2</sup>Institute of Chemical Research of Catalonia (ICIQ), Barcelona Institute of Science and Technology, Av. Països Catalans 16, 43007 Tarragona, Spain.

Corresponding author: calmansa@welab.barcelona

## **Table of Contents:**





- Analytical data of final compounds: purity,  $^1\text{H}$  NMR, HRMS, page S2.
- $^{13}\text{C}$  NMR data for selected final compounds, page S11.
- $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra figures of compounds **45cS** and **59S**, page S13.
- Enantiomeric excess by chiral HPLC and optical rotation of enantiopure compounds, page S15.
- Chemical characterization of intermediates, page S17.
- HPLC traces of final compounds, page S28.
- HPLC traces ee determination of final compounds, page S40.





**Analytical data of final compounds: purity,  $^1\text{H}$  NMR, HRMS.**

Comp.	Structure	Purity (%)	$^1\text{H}$ NMR	HRMS
15-1		98.0	$^1\text{H}$ NMR (500 MHz, $\text{CDCl}_3$ ) δ 8.82 (bs, 1H), 7.97 (t, $J = 1.5$ Hz, 1H), 7.92 (dt, $J = 1.5, 7.7$ Hz, 1H), 7.58 (t, $J = 7.7$ Hz, 1H), 7.53-7.51 (m, 1H), 4.09-4.07 (m, 2H), 3.87-3.85 (m, 2H), 3.35 (s, 3H), 2.64 (s, 3H), 2.59 (s, 3H).	383.1275 [M+H] <sup>+</sup>
16a		98.4	$^1\text{H}$ NMR (400 MHz, $\text{CDCl}_3$ ) δ 8.72 (bs, 1H), 7.95 (t, $J = 1.5$ Hz, 1H), 7.90 (dt, $J = 1.7, 7.0$ Hz, 1H), 7.47-7.54 (m, 2H), 5.78 (bs, 1H), 4.04-4.02 (m, 2H), 3.78-3.75 (m, 2H), 3.47 (m, 2H), 3.23 (s, 3H), 2.60 (s, 3H), 1.24 (t, $J = 7.2$ Hz, 3H).	380.1831 [M+H] <sup>+</sup>
16b		97.4	$^1\text{H}$ NMR (500 MHz, $\text{CDCl}_3$ ) δ 8.82 (bs, 1H), 7.97 (m, 1H), 7.91 (dt, $J = 1.5, 7.3$ Hz, 1H), 7.56-7.51 (m, 2H), 4.06-4.04 (m, 2H), 3.78-3.77 (m, 2H), 3.74-3.70 (m, 2H), 3.24 (s, 3H), 3.19 (s, 3H), 2.63 (s, 3H), 1.21 (t, $J = 7.0$ Hz, 3H).	394.1985 [M+H] <sup>+</sup>
16c		99.2	$^1\text{H}$ NMR (500 MHz, $\text{CDCl}_3$ ) δ 8.75 (bs, 1H), 7.96 (t, $J = 1.5$ Hz, 1H), 7.91 (dt, $J = 1.5, 7.5$ Hz, 1H), 7.55-7.49 (m, 2H), 5.66 (bs, 1H), 4.05-4.03 (m, 2H), 3.79-3.78 (m, 2H), 3.27 (s, 3H), 3.02 (d, $J = 4.8$ Hz, 3H), 2.62 (s, 3H).	366.1689 [M+H] <sup>+</sup>

<b>16d</b>		95.4	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.76 (bs, 1H), 7.97 (t, J = 1.5 Hz, 1H), 7.92 (dt, J = 1.5, 7.5 Hz, 1H), 7.56-7.49 (m, 2H), 5.70 (bs, 1H), 4.06-4.04 (m, 2H), 3.79-3.78 (m, 2H), 3.59 (t, J = 5.2 Hz, 2H), 3.41 (s, 3H), 3.24 (s, 3H), 2.62 (s, 3H).	410.1942 [M+H] <sup>+</sup>
<b>17</b>		99.0	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.78 (bs, 1H), 7.94 (t, J = 1.5 Hz, 1H), 7.90 (dt, J = 1.5, 7.2 Hz, 1H), 7.56-7.46 (m, 2H), 5.56 (bs, 1H), 4.03-4.00 (m, 2H), 3.80-3.73 (m, 4H), 3.50-3.41 (m, 2H), 2.61 (s, 3H), 1.25 (t, J = 7.2 Hz, 3H), 1.23 (t, J = 7.2 Hz, 3H).	394.1995 [M+H] <sup>+</sup>
<b>23</b>		95.1	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.78 (bs, 1H), 7.39 (m, 1H), 7.34-7.29 (m, 2H), 6.88-6.85 (m, 1H), 5.14 (bs, 1H), 4.48 (s, 2H), 3.80-3.76 (m, 4H), 3.42-3.35 (m, 2H), 3.12 (s, 3H), 2.62 (s, 3H), 1.20 (t, J = 7.2 Hz, 3H).	366.2031 [M+H] <sup>+</sup>
<b>31aR</b>		97.2	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.58 (bs, 1H), 7.48-7.46 (m, 2H), 7.42-7.38 (m, 2H), 7.34-7.26 (m, 2H), 6.92-6.91 (m, 1H), 6.89-6.85 (m, 2H), 5.42 (dd, J = 4.8, 8.0 Hz, 1H), 3.94-3.92 (m, 2H), 3.77-3.76 (m, 2H), 3.52-3.47 (m, 2H), 3.29 (s, 3H), 2.85-2.73 (m, 2H), 2.44 (s, 3H), 2.31-2.20 (m, 1H), 2.14-2.06 (m, 1H), 1.29 (t, J = 7.2 Hz, 3H).	461.2670 [M+H] <sup>+</sup>
<b>31aS</b>		95.9	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.58 (bs, 1H), 7.48-7.46 (m, 2H), 7.42-7.38 (m, 2H), 7.34-7.26 (m, 2H), 6.92-6.91 (m, 1H), 6.89-6.85 (m, 2H), 5.42 (dd, J = 4.8, 8.0 Hz, 1H), 3.94-3.92 (m, 2H), 3.77-3.76 (m, 2H), 3.52-3.47 (m, 2H), 3.29 (s, 3H), 2.85-2.73 (m, 2H), 2.44 (s, 3H), 2.31-2.20 (m, 1H), 2.14-2.06 (m, 1H), 1.29 (t, J = 7.2 Hz, 3H).	461.2670 [M+H] <sup>+</sup>

<b>31b</b>		97.2	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.56 (bs, 1H), 7.47-7.45 (m, 2H), 7.41-7.37 (m, 2H), 7.33-7.29 (m, 1H), 7.14 (d, J = 8.9 Hz, 2H), 6.99 (d, J = 8.9 Hz, 2 H), 5.41 (dd, J = 4.7, 8.1 Hz, 1H), 3.92-3.90 (m, 2H), 3.78-3.76 (m, 2H), 3.51-3.46 (m, 2H), 3.28 (s, 3H), 2.86-2.73 (m, 2H), 2.44 (s, 3H), 2.31-2.20 (m, 1H), 2.14-2.05 (m, 1H), 1.28 (t, J = 7.2 Hz, 3H).	461.2663 [M+H] <sup>+</sup>
<b>31c</b>		99.1	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.62 (bs, 1H), 7.47-7.33 (m, 5H), 7.41-7.37 (m, 2H), 7.33-7.29 (m, 1H), 7.14 (d, J = 8.9 Hz, 2H), 6.99 (d, J = 8.9 Hz, 2 H), 5.41 (dd, J = 4.7, 8.1 Hz, 1H), 3.92-3.90 (m, 2H), 3.78-3.76 (m, 2H), 3.51-3.46 (m, 2H), 3.28 (s, 3H), 2.86-2.73 (m, 2H), 2.44 (s, 3H), 2.31-2.20 (m, 1H), 2.14-2.05 (m, 1H), 1.28 (t, J= 7.2 Hz, 3H).	461.2654 [M+H] <sup>+</sup>
<b>31d</b>		99.5	<sup>1</sup> H NMR (500 MHz, CD <sub>3</sub> OD) δ 8.62 (bs, 1H), 7.51-7.43 (m, 5H), 7.26 (dd, J = 1.6, 7.8 Hz, 1 H), 7.18 (t, J = 7.3 Hz, 1H), 7.17 (t, J= 7.3 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 5.44 (bs, 1H), 4.00 (m, 4H), 3.55-3.50 (m, 2H), 3.36 (s, 3H), 2.70 (t, J= 6.7 Hz, 2H), 2.33 (s, 3H), 2.24-2.15 (m, 1H), 2.10-2.09 (m, 1H), 1.31 (t, J = 7.2 Hz, 3H).	475.2806 [M+H] <sup>+</sup>
<b>31e</b>		100	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.54 (s, 1H), 7.39-7.33 (m, 5H), 7.31-7.28 (m, 1H), 7.26-7.24 (m, 3H), 4.47 (dd, J = 5.1, 8.2 Hz, 1H), 4.40 (d, J = 12.0 Hz, 1H), 4.28 (d, J = 12.1 Hz, 1H), 3.95-3.94 (m, 2H), 3.77-3.75 (m, 2H), 3.44-3.40 (m, 2H), 3.23 (s, 3H), 2.68-2.64 (m, 1H), 2.60-2.55 (m, 1H), 2.32 (s, 3H), 2.06-1.99 (m, 1H), 1.89-1.82 (m, 1H), 1.22 (t, J = 7.2 Hz, 3H).	475.2718 [M+H] <sup>+</sup>




<b>31f</b>		97.0	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.68 and 8.65 (bs, 1H), 7.55 and 7.43 (bs, 1H), 7.36-7.21 (m, 7H), 7.13-7.09 (m, 1H), 4.42-4.17 (m, 3H), 3.87-3.42 (m, 6H), 3.16 and 3.12 (s, 3H), 2.66-2.55 (m, 2H), 2.36 (s, 3H), 2.07-1.91 (m, 1H), 1.87-1.80 (m, 1H), 1.23 (t, J = 7.2 Hz, 3H).	475.2819 [M+H] <sup>+</sup>
<b>32</b>		96.1	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.50 (bs, 1H), 7.40-7.38 (m, 2H), 7.34-7.30 (m, 2H), 7.26-7.18 (m, 2H), 6.84-6.83 (m, 1H), 6.81-6.76 (m, 2H), 5.31 (dd, J = 4.7, 7.9 Hz, 1H), 3.85-3.84 (m, 2H), 3.69-3.67 (m, 2H), 3.42 (q, J = 7.1, 16.0 Hz, 2H), 3.21 (s, 3H), 2.59-2.41 (m, 2H), 2.24 (s, 6H), 2.21-2.13 (m, 1H), 2.05-1.96 (m, 1H), 1.21 (t, J = 7.1 Hz, 3H).	475.2817 [M+H] <sup>+</sup>
<b>33R</b>		97.9	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.76 (s, 1H), 7.36-7.30 (m, 4H), 7.26-7.23 (m, 1H), 7.16 (t, J = 8.0 Hz, 1H), 6.77-6.71 (m, 3H), 5.24 (dd, J = 4.7, 8.0 Hz, 1H), 4.67 (s, 1H), 3.78-3.63 (m, 5H), 3.48-3.43 (m, 2H), 2.74 (bs, 2H), 2.42 (s, 3H), 2.20-2.13 (m, 1H), 2.06-1.96 (m, 3), 1.88-1.78 (m, 1H), 1.58-1.49 (m, 1H), 1.23 (t, J = 7.2 Hz, 3H).	487.2810 [M+H] <sup>+</sup>
<b>33S</b>		98.2	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.77 (s, 1H), 7.35-7.30 (m, 4H), 7.26-7.23 (m, 1H), 7.15 (t, J = 8.0 Hz, 1H), 6.79-6.76 (m, 2H), 6.68 (dd, J = 8.3, 1.9 Hz, 1H), 5.24 (dd, J = 8.0, 4.7 Hz, 1H), 4.67 (s, 1H), 3.88-3.83 (m, 1H), 3.80-3.71 (m, 2H), 2.69-2.62 (m, 2H), 3.48-3.42 (m, 2H), 2.74 (bs, 2H), 2.42 (s, 3H), 2.22-2.10 (m, 1H), 2.03-1.97 (m, 2H), 1.89-1.79 (m, 1H), 1.61-1.52 (m, 1H), 1.23 (t, J = 7.2 Hz, 3H).	487.2809 [M+H] <sup>+</sup>

34		97.5	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.65 (s, 2H), 7.38-7.36 (m, 2H), 7.33-7.30 (m, 2H), 7.25-7.22 (m, 2H), 6.86-6.84 (m, 1H), 6.75-6.74 (m, 2H), 5.31 (dd, J = 4.7, 8.0 Hz, 1H), 3.99-3.88 (m, 2H), 2.88 (s, 3H), 2.75-2.66 (m, 2H), 2.36 (s, 3H), 2.22-2.15 (m, 1H), 2.06-1.99 (m, 1H), 1.08 (t, J = 7.2 Hz, 3H).	420.2380 [M+H] <sup>+</sup>
43S		100%	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.56 (s, 1H), 7.32 (dd, J = 1.1 Hz, J = 5.2 Hz, 1H), 7.25 (t, 1H), 7.10 (dd, J = 0.9, 3.5 Hz, 1H), 6.95-6.89 (m, 3H), 6.84 (ddd, J = 0.8, 1.9, 7.9 Hz, 1H), 5.67 (dd, J = 5.7, 7.6, 1H), 3.93-3.91 (m, 2H), 3.81-3.79 (m, 2H), 3.30 (s, 3H), 2.75-2.62 (m, 2H), 2.54 (s, 3H), 2.36 (s, 3H) 2.33-2.23 (m, 1H), 2.14-2.06 (m, 1H).	470.1687 [M+H] <sup>+</sup>
45aR		99.6%	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.52 (s, 1H), 7.32 (dd, J = 1.1, 5.2 Hz, 1H), 7.24 (t, J = 8.2 Hz, 1H), 7.10 (dd, J = 0.7, 3.5 Hz, 1H), 6.95 (dd, J = 3.5, 5.1 Hz, 1H), 6.92-6.88 (m, 2H), 6.83 (ddd, J = 0.7, 1.7, 8.2 Hz, 1H), 5.67 (dd, J = 5.7, 7.5 Hz, 1H), 3.89-3.87 (m, 2H), 3.73-3.71 (m, 2H), 3.45-3.40 (m, 2H), 3.22 (s, 3H), 2.72-2.66 (m, 2H), 2.36 (s, 3H), 2.36-2.25 (m, 1H), 2.14-2.06 (m, 1H), 1.22 (t, J = 7.2 Hz, 3H).	467.2234 [M+H] <sup>+</sup>
45aS		99.3%	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.52 (s, 1H), 7.32 (dd, J = 1.1, 5.2 Hz, 1H), 7.24 (t, J = 8.2 Hz, 1H), 7.10 (dd, J = 0.7, 3.5 Hz, 1H), 6.95 (dd, J = 3.5, 5.1 Hz, 1H), 6.92-6.88 (m, 2H), 6.83 (ddd, J = 0.7, 1.7, 8.2 Hz, 1H), 5.67 (dd, J = 5.7, 7.5 Hz, 1H), 3.89-3.87 (m, 2H), 3.73-3.71 (m, 2H), 3.45-3.40 (m, 2H), 3.22 (s, 3H), 2.72-2.66 (m, 2H), 2.36 (s, 3H), 2.36-2.25 (m, 1H), 2.14-2.06 (m, 1H), 1.22 (t, J = 7.2 Hz, 3H).	467.2233 [M+H] <sup>+</sup>

45b		100%	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.58 (s, 1H), 7.32 (dd, J = 1.2, 5.1 Hz, 1H), 7.24 (t, 1H), 7.10 (dd, J = 1.1, 3.3 Hz, 1H), 6.95 (dd, J = 3.6, 5.1 Hz, 1H), 6.92-6.88 (m, 2H), 6.83 (ddd, J = 0.7, 1.9, 8.0 Hz, 1H), 5.68 (dd, J = 5.4, 7.5, 1H), 3.88-3.86 (m, 2H), 3.72-3.70 (m, 2H), 3.21 (s, 3H), 3.18 (s, 6H), 2.85-2.72 (m, 2H), 2.41 (s, 3H), 2.35-2.27 (m, 1H), 2.17-2.10 (m, 1H).	467.2230 [M+H] <sup>+</sup>
45cS		100%	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.52 (s, 1H), 7.30 (d, J = 4.9 Hz, 1H), 7.23 (t, 1H), 7.09 (d, J = 3.6 Hz, 1H), 6.94-6.87 (m, 3H), 6.81 (d, J = 7.9 Hz, 1H), 5.66 (dd, J = 5.8, 7.7, 1H), 3.85-3.83 (m, 2H), 3.68-3.66 (m, 2H), 3.17 (s, 3H), 2.75-2.62 (m, 2H), 2.35 (s, 3H), 2.33-2.24 (m, 1H), 2.14-2.06 (m, 1H).	439.1902 [M+H] <sup>+</sup>
46S		99.2%	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.72 (s, 1H), 8.56 (s, 1H), 7.32 (dd, J = 0.9, 4.9 Hz, 1H), 7.27 (t, 1H), 7.10 (d, J = 3.3 Hz, 1H), 6.96-6.91 (m, 3H), 6.87 (d, J = 8.0 Hz, 1H), 5.68 (dd, J = 5.7, 7.7 Hz, 1H), 3.95-3.93 (m, 2H), 3.84-3.82 (m, 2H), 3.28 (s, 3H), 2.76-2.63 (m, 2H), 2.36 (s, 3H), 2.34-2.24 (m, 1H), 2.15-2.06 (m, 1H).	424.1808 [M+H] <sup>+</sup>
47S		96.1%	<sup>1</sup> H NMR (400 MHz, CD <sub>3</sub> OD) δ 8.74 (s, 1H), 7.40 (dd, J = 1.1, 5.0 Hz, 1H), 7.34 (t, 1H), 7.18 (dd, J = 1.1, 3.5 Hz, 1H), 7.04-6.98 (m, 3H), 6.94 (ddd, J = 0.8, 1.9, 7.9 Hz, 1H), 5.76 (dd, J = 5.7, 7.5, 1H), 4.01-3.99 (m, 2H), 3.90-3.88 (m, 2H), 3.36 (s, 3H), 2.84-2.71 (m, 2H), 2.58 (s, 3H), 2.44 (s, 3H), 2.42-2.31 (m, 1H), 2.21-2.14 (m, 1H).	438.1959 [M+H] <sup>+</sup>



61S		95.0%	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.95 (d, J = 7.6 Hz, 1H), 7.26-7.21 (m, 2H), 7.02 (d, J = 3.4 Hz, 1H), 6.95-6.89 (m, 3H), 6.85 (ddd, J = 0.9, 2.4 Hz, 8.4 Hz, 1H), 6.64 (d, J = 7.7 Hz, 1H), 5.57 (dd, J = 5.3, 7.5 Hz, 1H), 3.89-3.86 (m, 2H), 3.60-3.57 (m, 2H), 3.09 (s, 3H), 2.77-2.69 (m, 2H), 2.44 (s, 3H), 2.42 (s, 3H), 2.34-2.21 (m, 1H), 2.14-2.03 (m, 1H).	437.2010 [M+H] <sup>+</sup>
63S		99.5%	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.95 (d, J = 8.5 Hz, 1H), 7.33 (dd, J = 1.0, 5.0 Hz, 1H), 7.26 (t, J = 7.9 Hz, 1H), 7.12 (d, J = 3.4 Hz, 1H), 6.96-6.94 (m, H), 6.91 (dd, J = 2.8 Hz, J = 8.2 Hz, 1H), 6.86 (dd, J = 1.0 Hz, J = 7.9 Hz, 1H), 6.13 (d, J = 8.4 Hz, 1H), 5.71 (dd, J = 5.3, 7.6 Hz, 1H), 3.92 (s, 3H), 3.89-3.87 (m, 2H), 3.68-3.66 (m, 2H), 3.16 (s, 3H), 2.94-2.79 (m, 2H), 2.47 (s, 3H), 2.42 (s, 3H), 2.39-2.30 (m, 1H), 2.21-2.13 (m, 1H).	453.1948 [M+H] <sup>+</sup>
65		96.6%	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.34 (d, J = 3.9 Hz, 1H), 7.33-7.20 (m, 4H), 7.05-6.98 (m, 3H), 6.93 (dd, J = 3.5, 5.1 Hz, 1H), 6.85 (dd, J = 1.9, 8.2 Hz, 1H), 5.57 (dd, J = 5.6, 7.6 Hz, 1H), 3.78-3.74 (m, 2H), 3.33-3.29 (m, 2H), 2.86 (s, 3H), 2.75-2.70 (m, 2H), 2.41 (s, 3H), 2.35-2.20 (m, 1H), 2.14-2.03 (m, 1H).	423.1863 [M+H] <sup>+</sup>
67		99.1%	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.31 (s, 1H), 8.29 (d, J = 4.8 Hz, 1H), 7.55 (d, J = 4.9 Hz, 1H), 7.29-7.25 (m, 2H), 7.05 (d, J = 3.2 Hz, 1H), 7.00 (t, J = 2.0 Hz, 1H), 6.98-6.95 (m, 2H), 6.89 (dd, J = 2.1, 8.4 Hz, 1H), 5.60 (dd, J = 5.4, 7.6 Hz, 1H), 3.81-3.79 (m, 2H), 3.45-3.40 (m, 2H), 3.00 (s, 3H), 2.81-2.72 (m, 2H), 2.45 (s, 3H), 2.35-2.28 (m, 1H), 2.15-2.09 (m, 1H).	423.1856 [M+H] <sup>+</sup>


69		97.0%	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.62 (dd, J = 1.6, 7.6 Hz, 1H), 7.41 (td, J = 1.8, 7.7 Hz, 1H), 7.23-7.19 (m, 2H), 7.10 (d, J = 3.4 Hz, 1H), 7.03-6.90 (m, 5H), 6.83 (dd, J = 2.0, 8.2 Hz, 1H), 5.75 (dd, J = 5.1, 8.4 Hz, 1H), 3.76-3.73 (m, 2H), 3.31-3.29 (m, 2H), 3.13-3.03 (m, 2H), 2.87 (s, 3H), 2.57 (s, 3H), 2.54-2.45 (m, 1H), 2.38-2.27 (m, 1H).	422.1909 [M+H] <sup>+</sup>
71R		96.6%	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.21-7.14 (m, 2H), 7.99 (dd, J = 3.2, 5.1 Hz, 1H), 6.78-6.74 (m, 3H), 5.52 (dd, J = 5.4, 7.8 Hz, 1H), 3.75 (d, J = 6.2 Hz, 2H), 3.31-3.29 (m, 2H), 2.82-2.79 (m, 2H), 2.75-2.62 (m, 6H), 2.39 (s, 3H), 2.39 (s, 3H), 2.30-2.21 (m, 1H), 2.10-2.01 (m, 1H).	374.1908 [M+H] <sup>+</sup>
71S		98.7%	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.21-7.14 (m, 2H), 7.99 (dd, J = 3.2 Hz, J = 5.1 Hz, 1H), 6.78-6.74 (m, 3H), 5.52 (dd, J = 5.4, 7.8 Hz, 1H), 3.75 (d, J = 6.2 Hz, 2H), 3.31-3.29 (m, 2H), 2.82-2.79 (m, 2H), 2.75-2.62 (m, 6H), 2.39 (s, 3H), 2.39 (s, 3H), 2.30-2.21 (m, 1H), 2.10-2.01 (m, 1H).	374.1895 [M+H] <sup>+</sup>

**<sup>13</sup>C NMR data for selected final compounds.**


Comp.	Structure	<sup>13</sup> C NMR
15-1		<sup>13</sup> C NMR (100 MHz, CDCl <sub>3</sub> ) δ 174.39, 166.99, 164.18, 161.72, 156.81, 143.90, 130.04, 129.26, 125.16, 125.00, 123.94, 108.18, 55.23, 48.99, 38.69, 14.14, 11.11.
16a		<sup>13</sup> C NMR (100 MHz, CDCl <sub>3</sub> ) δ 167.62, 164.25, 163.74, 163.67, 162.07, 158.50, 144.34, 129.81, 129.33, 124.86, 124.49, 124.05, 54.92, 49.17, 38.41, 36.19, 14.81, 11.02.
31aR		<sup>13</sup> C NMR (100 MHz, CD <sub>3</sub> OD) δ 168.37, 162.44, 158.68, 158.49, 144.73, 141.47, 129.56, 128.37, 127.49, 125.89, 118.42, 114.28, 114.23, 78.27, 54.43, 49.71, 47.50, 37.64, 37.48, 35.72, 34.70, 13.74.
45cS		<sup>13</sup> C NMR (100 MHz, CD <sub>3</sub> OD) δ 168.08, 163.19, 162.62, 158.73, 158.41, 144.71, 144.59, 129.64, 126.31, 125.38, 124.98, 118.88, 114.54, 114.50, 103.44, 74.57, 54.53, 49.64, 47.55, 37.84, 37.62, 34.78.

<b>59S</b>		<sup>13</sup> C NMR (100 MHz, CDCl <sub>3</sub> ) δ 168.78, 158.63, 155.56, 151.22, 144.97, 143.72, 140.87, 129.85, 126.59, 124.89, 124.83, 119.64, 118.90, 114.68, 114.51, 114.34, 74.99, 56.81, 49.17, 4817, 38.76, 36.53.
------------	--	--

#### <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra figures of compounds 45cS and 59S.



<sup>1</sup>H-NMR and <sup>13</sup>C-NMR of the free base of compound **45cS**



**Enantiomeric excess by chiral HPLC and optical rotation of enantiopure compounds.**

Comp.	ee (%)	Chiral Chromatographic conditions	Optical rotation [α]20D
<b>31aR</b>	100	Method 3	+8.3 (c, 0.18, MeOH)
<b>31aS</b>	100	Method 3	-3.9 (c, 0.07, MeOH)
<b>33R</b>	(ed)	Method 5	+41.8 (c, 0.17, MeOH)
	100		
<b>33S</b>	(ed)	Method 5	+66.3 (c, 0.12, MeOH)
	100		
<b>43S</b>	99.4	Method 4	-43.8 (c, 0.19, MeOH)
<b>45aR</b>	100	Method 4	+42.29 (c, 0.17, MeOH)
<b>45aS</b>	98.0	Method 4	-41.9 (c, 0.20, MeOH)
<b>45cS</b>	99.1	Method 3	-44.4 (c, 0.17, MeOH)
<b>46S</b>	99.5	Method 5	-38.8 (c, 0.18, MeOH)
<b>47S</b>	100	Method 5	-30.5 (c, 0.19, MeOH)
<b>56S</b>	98.9	Method 3	-46.9 (c, 0.17, MeOH)
<b>57S</b>	100	Method 5	-35.1 (c, 0.17, MeOH)

<b>59S</b>	100	Method 5	-32.1 (c, 0.17, MeOH)
<b>61S</b>	100	Method 5	-36.3 (c, 0.04, MeOH)
<b>63S</b>	99.2	Method 4	-35.1 (c, 0.17, MeOH)
<b>71R</b>	95.8	Method 4	+48.2 (c, 0.21, MeOH)
<b>71S</b>	96.3	Method 4	-47.1 (c, 0.48, MeOH)

Methods described in the experimental part




**Chemical characterization of intermediates.**

Intermediate	Structure	Chemical Name	NMR
15-2		9-Ethyl-6-(3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-2-(methylthio)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-e][1,4]diazepin-5-one	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.80 (s, 1H), 7.94 (t, J = 1.5 Hz, 1H), 7.91 (dt, J = 1.5, 7.7 Hz, 1H), 7.53 (t, J = 8 Hz, 1H), 7.47 (m, 1H), 4.03 (m, 2H), 3.83 (m, 4H), 3.81 (q, J = 7.1 Hz, 2H), 2.60 (s, 3H), 2.53 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H).
26R-meta		(R)-1-(3-Chloro-1-phenylpropoxy)-3-iodobenzene	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 7.41-7.36 (m, 4H), 7.32 (m, 1H), 7.29 (m, 1H), 7.25 (m, 1H), 6.91 (t, J = 8.5 Hz, 1H), 6.82 (m, 1H), 5.37 (m, 1H), 3.84-3.77 (m, 1H), 3.65-3.58 (m, 1H), 2.53-2.43 (m, 1H), 2.28-2.18 (m, 1H).
27-1R-meta		tert-Butyl (R)-(3-(3-iodophenoxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 7.41-7.26 (m, 5H), 7.25 (m, 1H), 7.21 (m, 1H), 6.88 (t, J = 8.5 Hz, 1H), 6.77 (m, 1H), 5.10 (m, 1H), 3.56-3.26 (m, 2H), 2.87 (s, 3H), 2.28-2.01 (m, 2H), 1.52-1.33 (bs, 9H).
27-1-ortho		tert-Butyl (3-(2-iodophenoxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 7.74 (dd, J = 1.6, 7.8 Hz, 1H), 7.34-7.22 (m, 5H), 7.07 (td, J = 1.6, 7.8 Hz, 1H), 6.61 (td, J = 1.2, 7.6 Hz, 1H), 6.55 (d, J = 8.2 Hz, 1H), 5.21-5.17 (m, 1H), 3.63-3.28 (m, 2H), 2.86 (s, 3H), 2.27-2.01 (m, 2H), 1.38 (s, 9H).

<b>27-1-para</b>		<i>tert</i> -Butyl (3-(4-bromophenoxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.34-7.24 (m, 5H), 6.69 (d, J = 8.9 Hz, 2H), 5.07-5.04 (m, 1H), 3.49-3.27 (m, 2H), 2.84 (s, 3H), 2.20-2.01 (m, 2H), 1.39 (bs, 9H).
<b>27-2-meta</b>		<i>tert</i> -Butyl (3-((3-bromobenzyl)oxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.48 (s, 1H), 7.44-7.37 (m, 3H), 7.37-7.30 (m, 3H), 7.26-7.19 (m, 2H), 4.40 (d, J = 12.1 Hz, 1H), 4.34 (m, 1H), 4.25 (d, J = 12.1 Hz, 1H), 3.41-3.22 (m, 2H), 2.85 (s, 3H), 2.07 (m, 1H), 1.94 (m, 1H), 1.45 (s, 9H).
<b>27-2-ortho</b>		<i>tert</i> -Butyl (3-((2-bromobenzyl)oxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 7.51 (d, J = 7.9 Hz, 2H), 7.38-7.29 (m, 5H), 7.14 (td, , J = 1.4, 7.6 Hz, 1H), 4.46-4.33 (m, 3H), 3.40-3.20 (m, 2H), 2.82 (s, 3H), 2.17-1.91 (m, 2H), 1.41 (s, 9H).
<b>27-2-para</b>		<i>tert</i> -Butyl (3-((4-bromobenzyl)oxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 7.45 (d, J = 8.3 Hz, 2H), 7.37-7.28 (m, 5H), 7.17 (d, , J = 8.3 Hz, 2H), 4.36 (d, J = 11.9 Hz, 1H), 4.32 (dd, J = 4.8, 8.3 Hz, 1H), 4.21 (d, J = 12.1 Hz, 1H), 3.39-3.21 (m, 2H), 2.82 (s, 3H), 2.08-2.01 (m, 1H), 1.94-1.87 (m, 1H), 1.43 (s, 9H).
<b>30-1a</b>		<i>tert</i> -Butyl (R)-methyl(3-(3-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-phenylpropyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.78 (s, 1H), 7.35 (m, 4H), 7.28 (m, 1H), 7.20 (m, 1H), 6.82 (m, 2H), 6.72 (m, 1H), 5.13 (m, 1H), 3.90 (m, 2H), 3.71 (m, 2H), 3.41 (m, 2H), 3.28 (s, 3H), 2.86 (s, 3H), 2.57 (s, 3H), 2.14 (m, 2 H), 1.42 (s, 9H).

<b>30-1b</b>		<i>tert</i> -Butyl methyl(3-(4-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-phenylpropyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.73 (s, 1H), 7.32 (m, 4H), 7.26 (m, 1H), 7.06 (d, J = 9 Hz, 2H), 6.84 (d, J = 9 Hz, 2H), 5.10 (m, 1H), 3.87 (m, 2H), 3.71 (m, 2H), 3.40 (m, 2H), 3.24 (s, 3H), 2.85 (s, 3H), 2.52 (s, 3H), 2.21-2.02 (m, 2H), 1.41 (s, 9H).
<b>30-1c</b>		<i>tert</i> -Butyl methyl(3-(2-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-phenylpropyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.88 (s, 1H), 7.38-7.25 (m, 5H), 7.21 (dd, J = 1.4, 7.7 Hz, 1H), 7.11 (t, J = 7.8 Hz, 1H), 6.94 (t, J = 7.8 Hz, 2H), 6.76 (d, J = 8.5 Hz, 1H), 5.19 (m, 1H), 3.95 (m, 2H), 3.87 (m, 2H), 3.32 (s, 3H), 3.28 (m, 2H), 2.74 (s, 3H), 2.58 (s, 3H), 2.10 (m, 2H), 1.39 (bs, 9H).
<b>30-2d</b>		<i>tert</i> -Butyl methyl(3-((3-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)benzyl)oxy)-3-phenylpropyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.79 (s, 1H), 7.36 (m, 6H), 7.22 (m, 3H), 4.42 (m, 1H), 4.35 (m, 1H), 4.29 (m, 1H), 4.00 (m, 2H), 3.80 (m, 2H), 3.35 (m, 2H), 3.29 (s, 3H), 2.82 (s, 3H), 2.56 (s, 3H), 2.06 (m, 1H), 1.92 (m, 1H), 1.43 (s, 9H).
<b>30-2e</b>		<i>tert</i> -Butyl methyl(3-((4-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)benzyl)oxy)-3-phenylpropyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.78 (s, 1H), 7.39-7.23 (m, 9H), 4.41 (d, J = 11.8 Hz, 1H), 4.35 (dd, J = 4.8, 8.4 Hz, 1 H), 4.26 (d, J = 11.8 Hz, 1 H), 3.99-3.97 (m, 2H), 3.80-3.78 (m, 2H), 3.34 (bs, 2H), 3.28 (s, 3H), 2.82 (s, 3H), 2.54 (s, 3H), 2.09-2.00 (m, 1H), 1.92-1.87 (bs, 1H), 1.42 (s, 9H).
<b>30-2f</b>		<i>tert</i> -Butyl methyl(3-((2-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-phenylpropyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.72-8.66 (m, 1H), 7.57-7.43 (m, 1H), 7.32-7.25 (m, 7H), 7.10-7.09 (m, 1H), 4.31-4.27 (m,

		yl)benzyl)oxy)-3-phenylpropyl)carbamate	3H), 3.84-3.51 (m, 4H), 3.23-3.17 (m, 5H), 2.77 (bs, 3H), 2.53 (s, 3H), 2.14-1.89 (m, 2H), 1.40 (s, 9H).
<b>BOC intermediate for 31aR</b>		<i>tert</i> -Butyl ( <i>R</i> )-(3-(3-(2-(ethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.71 (s, 1H), 7.35 (m, 4H), 7.26 (m, 1H), 7.17 (m, 1H), 6.83 (m, 2H), 6.68 (m, 1H), 5.11 (m, 1H), 3.87 (m, 2H), 3.63 (m, 2H), 3.48 (m, 2H), 3.40 (m, 2H), 3.20 (s, 3H), 2.85 (s, 3H), 2.16 (m, 1H), 2.09 (m, 1H), 1.42 (s, 9H), 1.25 (t, J = 7 Hz, 3H).
<b>BOC intermediate for 31b</b>		<i>tert</i> -Butyl (3-(4-(2-(ethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.70 (s, 1H), 7.35 (m, 4H), 7.26 (m, 1H), 7.07 (d, J = 9 Hz, 2H), 6.84 (d, J = 9 Hz, 2H), 5.10 (m, 1H), 3.87 (m, 2H), 3.67 (m, 2H), 3.46 (m, 2H), 3.41 (m, 2H), 3.20 (s, 3H), 2.86 (s, 3H), 2.16 (m, 1H), 2.08 (m, 1H), 1.44 (s, 9H), 1.24 (t, J = 7.1 Hz, 3H).
<b>BOC intermediate for 31c</b>		<i>tert</i> -Butyl (3-(2-(2-(ethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.80 (s, 1H), 7.37-7.22 (m, 5H), 7.20 (dd, J = 1.4, 7.7 Hz, 1H), 7.07 (m, 1H), 6.91 (t, J = 7.7 Hz, 2H), 6.72 (d, J = 8 Hz, 1H), 5.17 (m, 1H), 3.91 (m, 2H), 3.81 (m, 2H), 3.48 (m, 2H), 3.29 (m, 2H), 3.24 (s, 3H), 2.72 (s, 3H), 2.09 (m, 2H), 1.37 (bs, 9H), 1.25 (t, J = 7.4 Hz, 3H).
<b>BOC intermediate for 31d</b>		<i>tert</i> -Butyl ((3-(2-(ethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)benzyl)oxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.73 (s, 1H), 7.35 (m, 6H), 7.21 (m, 3H), 5.26 (bs, 1H), 4.35 (m, 3H), 3.98 (m, 2H), 3.73 (m, 2H), 3.48 (m, 2H), 3.33 (m, 2H), 3.23 (s, 3H), 2.82 (s, 3H), 2.05 (m, 1H), 1.92 (m, 1H), 1.43 (s, 9H), 1.25 (t, J = 7 Hz,





			3H).
<b>BOC intermediate for 31e</b>		<i>tert</i> -Butyl (3-((4-(2-ethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)benzyl)oxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.73 (s, 1H), 7.40-7.30 (m, 7H), 7.27-7.23 (m, 2H), 4.41 (d, J=11.7 Hz, 1H), 4.34 (dd, J=4.8, 8.3 Hz, 1H), 4.25 (d, J=11.7 Hz, 1H), 3.98-3.95 (m, 2H), 3.73-3.70 (m, 2H), 3.51-3.42 (m, 2H), 3.31 (bs, 2H), 3.22 (s, 3H), 2.82 (s, 3H), 2.07-1.98 (m, 1H), 1.93-1.87 (m, 1H), 1.42 (s, 9H), 1.24 (t, J=7.2 Hz, 3H).
<b>BOC intermediate for 31f</b>		<i>tert</i> -Butyl (3-((2-(2-ethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)benzyl)oxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.65 (s, 1H), 7.59-7.10 (m, 9H), 5.80 (bs, 1H), 4.34-4.18 (m, 3H), 3.82-3.50 (m, 4H), 3.48-3.14 (m, 2H), 3.28 (m, 2H), 3.14 (s, 3H), 2.78 (s, 3H), 2.04-2.00 (m, 1H), 1.89 (m, 1H), 1.41 (s, 9H), 1.24 (t, J=7.2 Hz, 3H).
<b>BOC intermediate for 33</b>		<i>tert</i> -Butyl ((R)-3-((S)-2-(ethylamino)-5-oxo-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-f]pyrrolo[1,2-a][1,4]diazepin-6(7H)-yl)phenoxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.78 (s, 1H), 7.35-7.32 (m, 4H), 7.29-7.24 (m, 1H), 7.18 (t, J=8.0 Hz, 1H), 6.79 (m, 1H), 6.74 (m, 1H), 6.70 (m, 1H), 5.32 (bs, 1H), 5.12 (dd, J=4.1, 8.4 Hz, 1H), 3.80 (m, 3H), 3.70-3.65 (m, 2H), 3.50-3.39 (m, 4H), 2.86 (s, 3H), 2.18-2.00 (m, 4H), 1.91-1.78 (m, 1H), 1.61-1.50 (m, 1H), 1.42 (s, 9H), 1.24 (t, J=7.2 Hz, 3H).



<b>BOC and SMe intermediate for 33</b>		<i>tert</i> -Butyl methyl(( <i>R</i> )-3-(3-(( <i>S</i> )-2-(methylthio)-5-oxo-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-f]pyrrolo[1,2-a][1,4]diazepin-6(7H)-yl)phenoxy)-3-phenylpropyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.83 (s, 1H), 7.37-7.34 (m, 4H), 7.29-7.24 (m, 1H), 7.20 (t, J = 8.4 Hz, 1H), 6.80-6.78 (m, 1H), 6.75-6.73 (m, 2H), 5.13 (dd, J = 3.9, 8.3 Hz, 1H), 3.85-3.80 (m, 3H), 3.73-3.70 (m, 2H), 3.41 (m, 2H), 2.86 (s, 3H), 2.56 (s, 3H), 2.19-2.17 (m, 1H), 2.12-2.04 (m, 5H), 1.94-1.84 (m, 1H), 1.63-1.54 (m, 1H), 1.51 (s, 9H).
<b>BOC intermediate for 34</b>		<i>tert</i> -Butyl (3-(3-(2-(ethylamino)-N-methylpyrimidine-5-carboxamido)phenoxy)-3-phenylpropyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.65 (s, 2H), 7.34-7.19 (m, 5H), 6.81-6.74 (m, 2 H), 6.72 (m, 1H), 6.13 (m, 1H), 5.10 (dd, J = 4.2, 8.1 Hz, 1H), 3.97-3.83 (m, 2H), 3.47-3.35 (m, 2H), 2.97 (d, J = 4.8 Hz, 3H), 2.84 (s, 3H), 2.23-2.02 (m, 2H), 1.40 (s, 9H), 1.12 (t, J= 7.2 Hz, 3H).
<b>40S</b>		( <i>S</i> )-3-(3-Bromophenoxy)-N-methyl-3-(thiophen-2-yl)propan-1-amine	<sup>1</sup> H (400 MHz, CDCl <sub>3</sub> ) δ 7.25 (dd, J = 1.2, 5.1 Hz, 1H), 7.13 (m, 1H), 7.10-7.06 (m, 2H), 7.03 (m, 1H), 6.96 (dd, J = 3.4, 5.0 Hz, 1H), 6.87 (dt, J = 2.2, 7.2 Hz, 1H), 5.57 (dd, J = 5.2, 7.5 Hz, 1H), 2.78 (m, 2H), 2.47 (s, 3H), 2.32 (m, 1H), 2.24 (bs, 1H), 2.13 (m, 1H).
<b>41-1S</b>		<i>tert</i> -Butyl ( <i>S</i> )-(3-(3-bromophenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 7.25 (d, J = 5 Hz, 1H), 7.10 (m, 1H), 7.06 (m, 2H), 7.02 (m, 1H), 6.96 (m, 1H), 6.85 (td, J = 2.5, 7.0 Hz, 1H), 5.41 (m, 1H), 3.43 (m, 2H), 2.87 (s, 3H), 2.31 (m, 1H), 2.18 (m, 1H), 1.42 (s, 9H).

<b>41-2S</b>		2-(Trimethylsilyl)ethyl ( <i>S</i> )-(3-(3-bromophenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.21 (m, 1H), 7.11-7.05 (m, 3H), 7.03 (m, 1H), 6.92 (m, 1H), 6.83 (m, 1H), 5.42 (m, 1H), 4.19-3.93 (m, 2H), 3.57 (m, 1H), 3.37 (m, 1H), 2.89 (m, 3H), 2.29 (m, 1H), 2.16 (m, 1H), 0.99 (m, 1H), 0.81 (m, 1H), 0.03 s, 9H).
<b>42-1S</b>		<i>tert</i> -Butyl ( <i>S</i> )-methyl(3-(3-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.78 (s, 1H), 7.25 (m, 2H), 7.03 (m, 1H), 6.95 (m, 1H), 6.87 (m, 2H), 6.82 (m, 1H), 5.43 (m, 1H), 3.93 (m, 2H), 3.75 (m, 2H), 3.39 (m, 2H), 3.29 (s, 3H), 2.86 (s, 3H), 2.56 (s, 3H), 2.25 (m, 2H), 1.42 (s, 9H).
<b>42-2S</b>		2-(Trimethylsilyl)ethyl ( <i>S</i> )-methyl(3-(3-(9-methyl-2-(methylthio)-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.78 (s, 1H), 7.26 (m, 2H), 7.04 (m, 1H), 6.96 (m, 1H), 6.88 (m, 2H), 6.84 (m, 1H), 5.45 (m, 1H), 4.15 (m, 2H), 3.95 (m, 2H), 3.76 (m, 2H), 3.45 (m, 2H), 3.30 (s, 3H), 2.91 (s, 3H), 2.57 (s, 3H), 2.33 (m, 1H), 2.19 (m, 1H), 1.00 (m, 1H), 0.93 (m, 1H), 0.05 (s, 9H).
<b>BOC intermediate for 45a</b>		<i>tert</i> -Butyl ( <i>S</i> )-(3-(3-(2-(ethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.70 (s, 1H), 7.23-7.19 (m, 2H), 7.01 (d, J = 3.0 Hz, 1H), 6.93 (dd, J = 3.6, 5.0 Hz, 1H), 6.87-6.85 (m, 2H), 6.78 (ddd, J = 0.8, 2.2, 8.2 Hz, 1H), 5.41 (dd, J = 5.2, 7.8, 1H), 5.16 (bs, 1H), 3.90-3.88 (m, 2H), 3.67-3.65 (m, 2H), 3.50-3.43 (m, 2H), 3.41-3.33 (m, 2H), 3.20 (s, 3H), 2.84 (s, 3H), 2.32-2.26 (m, 1H), 2.20-2.11 (m, 1H), 1.41 (s, 9H), 1.23 (t, J = 7.3 Hz, 3H).

<b>Teoc intermediate for 45b</b>		2-(Trimethylsilyl)ethyl (3-(3-(2-(dimethylamino)-9-methyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.75 (s, 1H), 7.21-7.17 (m, 2H), 7.03-6.68 (m, 1H), 6.93-6.91 (m, 1H), 6.86-6.84 (m, 2H), 6.78-6.74 (m, 1H), 5.44-5.39 (m, 1H), 4.17-4.03 (m, 2H), 3.88-3.86 (m, 2H), 3.65-3.63 (m, 2H), 3.50-3.34 (m, 2H), 3.19 (s, 6H), 3.18 (s, 3H), 2.87 (s, 3H), 2.34-2.24 (m, 1H), 2.21-2.11 (m, 1H), 1.00-0.87 (m, 2H), 0.01 (s, 9H).
<b>Teoc intermediate for 46</b>		2-(Trimethylsilyl)ethyl (S)-methyl(3-(3-(9-methyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.91 (s, 1H), 8.69 (s, 1H), 7.27-7.23 (m, 2H), 7.04 (m, 1H), 6.95 (m, 1H), 6.88 (m, 2H), 6.84 (m, 1H), 5.45 (m, 1H), 4.20-4.05 (m, 2H), 3.94 (m, 2H), 3.77 (m, 2H), 3.51-3.39 (m, 2H), 3.28 (s, 3H), 2.90 (s, 3H), 2.32 (m, 1H), 2.19 (m, 1H), 0.99 (m, 1H), 0.92 (m, 1H), 0.037 (s, 9H).
<b>BOC intermediate for 47</b>		tert-Butyl (S)-(3-(3-(2,9-dimethyl-5-oxo-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.87 (s, 1H), 7.23 (m, 2H), 7.03 (m, 1H), 6.94 (m, 1H), 6.87 (m, 2H), 6.82 (m, 1H), 5.43 (m, 1H), 3.91 (m, 2H), 3.73 (m, 2H), 3.38 (m, 2H), 3.27 (s, 3H), 2.85 (s, 3H), 2.57 (s, 3H), 2.30 (m, 1H), 2-18 (m, 1H), 1.42 (s, 9H).
<b>Teoc intermediate for 48</b>		2-(Trimethylsilyl)ethyl methyl(3-(3-(9-methyl-5-oxo-2-(trifluoromethyl)-5,7,8,9-tetrahydro-6H-pyrimido[4,5-e][1,4]diazepin-6-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.99 (s, 1H), 7.27-7.20 (m, 2H), 7.03-6.83 (m, 5H), 5.45-5.35 (m, 1H), 4.17-4.02 (m, 2H), 3.95-3.92 (m, 2H), 3.80-3.77 (m, 2H), 3.49-3.38 (m, 2H), 3.30 (s, 3H), 2.88 (s, 3H), 2.37-2.09 (m, 2H), 0.97-0.83 (m, 2H), 0.01 (s, 9H).


<b>Teoc intermediate for 56</b>		2-(Trimethylsilyl)ethyl (S)-(3-(3-(8-(ethylamino)-1-methyl-5-oxo-1,2,3,5-tetrahydro-4H-pyrido[4,3-e][1,4]diazepin-4-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) δ 8.41 (s, 1H), 7.22-7.19 (m, 2H), 7.04-7.00 (m, 1H), 6.94-6.91 (m, 3H) 6.78 (d, J = 8.0 Hz, 1H), 5.45-5.41 (m, 1H), 4.94-4.91 (m, 1H), 4.16-4.05 (m, 2H), 3.87-3.85 (m, 2H), 3.51-3.45 (m, 2H), 3.45-3.35 (m, 2H), 3.31-3.26 (m, 2H), 2.92 (s, 3H), 2.88 (s, 3H), 2.34-2.26 (m, 1H), 2.22-2.12 (m, 1H), 1.28 (t, J = 7.2 Hz, 3H), 1.01-0.89 (m, 2H), 0.01 (s, 9H).
<b>Teoc intermediate for 57</b>		2-(Trimethylsilyl)ethyl (S)-(3-(3-(8-(ethylamino)-1-methyl-5-oxo-1,2,3,5-tetrahydro-4H-pyrido[2,3-e][1,4]diazepin-4-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 7.95 (d, J = 8.5 Hz, 1H), 7.27-7.19 (m, 2H), 7.03 (br, 1H), 6.95-6.90 (m, 3H), 6.78 (d, J = 8.0 Hz, 1H), 5.87 (d, J = 8.4 Hz, 1H), 5.46-5.42 (m, 1H), 4.63-4.59 (m, 1H), 4.17-4.10 (m, 2H), 3.91-3.88 (m, 2H), 3.60-3.57 (m, 2H), 3.45-3.31 (m, 4H), 3.09 (s, 3H), 2.90 (s, 3H), 2.35-2.28 (m, 1H), 2.22-2.12 (m, 1H), 1.26 (t, J = 7.2 Hz, 3H), 0.97 (bs, 2H), 0.04 (s, 9H).
<b>Teoc intermediate for 59</b>		2-(Trimethylsilyl)ethyl (S)-methyl(3-(3-(1-methyl-5-oxo-1,2,3,5-tetrahydro-4H-pyrido[2,3-e][1,4]diazepin-4-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.35 (dd, J = 1.8 Hz, J = 4.9 Hz, 1H), 8.05 (dd, J = 1.9, 7.5 Hz, 1H), 7.28-7.23 (m, 2H), 7.05 (br, 1H), 6.96-6.94 (m, 4H), 6.85-6.79 (m, 2H), 5.46-5.42 (m, 1H), 4.16-4.10 (m, 2H), 3.92-3.89 (m, 2H), 3.63-3.60 (m, 2H), 3.46-3.31 (m, 2H), 3.09 (s, 3H), 2.90 (s, 3H), 2.36-2.29 (m, 1H), 2.22-2.12 (m, 1H), 0.97 (bs, 2H), 0.04 (s, 9H).


<b>Teoc intermediate for 61</b>		2-(Trimethylsilyl)ethyl (S)-(3-(3-(1,8-dimethyl-5-oxo-1,2,3,5-tetrahydro-4H-pyrido[2,3-e][1,4]diazepin-4-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 7.93 (d, J = 7.5 Hz, 1H), 7.27-7.27 (m, 2H), 7.05 (br, 1H), 6.97-6.92 (m, 3H), 6.82 (d, J = 8.1 Hz, 1H), 6.65 (d, J = 7.1 Hz, 1H), 5.46-5.42 (m, 1H), 4.14 (bs, 2H), 3.92-3.89 (m, 2H), 3.63-3.60 (m, 2H), 3.45 (bs, 2H), 3.11 (s, 3H), 3.09 (s, 3H), 2.90 (s, 3H), 2.46 (s, 3H), 2.37-2.29 (m, 1H), 2.22-2.12 (m, 1H), 0.96 (bs, 2H), 0.04 (s, 9H).
<b>Teoc intermediate for 63</b>		2-(Trimethylsilyl)ethyl (S)-(3-(3-(8-methoxy-1-methyl-5-oxo-1,2,3,5-tetrahydro-4H-pyrido[2,3-e][1,4]diazepin-4-yl)phenoxy)-3-(thiophen-2-yl)propyl)(methyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.08 (d, J = 8.5 Hz, 1H), 7.27-7.21 (m, 2H), 7.05 (m, 1H), 6.95 (m, 1H), 6.93-6.89 (m, 2H), 6.81 (m, 1H), 6.19 (d, J = 8.5 Hz, 1H), 5.45 (m, 1H), 4.14 (m, 2H), 3.94 (s, 3H), 3.92 (m, 2H), 3.66 (m, 2H), 3.44 (m, 2H), 3.16 (s, 3H), 2.90 (s, 3H), 2.32 (m, 1H), 2.19 (m, 1H), 0.97 (m, 2H), 0.04 (s, 9H).
<b>Teoc intermediate for 65</b>		2-(Trimethylsilyl)ethyl methyl(3-(3-(1-methyl-5-oxo-1,2,3,5-tetrahydro-4H-pyrido[3,2-e][1,4]diazepin-4-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 8.36 (dd, J = 1.5 Hz, J = 4.3 Hz, 1H), 7.35-7.23 (m, 4H), 7.07-7.02 (m, 3H), 6.96-6.94 (m, 1H), 6.84 (d, J = 8.0 Hz, 2H), 5.46-5.42 (m, 1H), 4.14 (bs, 2H), 3.81-3.77 (m, 2H), 3.44 (bs, 2H), 3.36-3.32 (m, 2H), 2.91 (s, 3H), 2.88 (s, 3H), 2.39-2.27 (m, 1H), 2.20 (bs, 1H), 0.97 (bs, 2H), 0.04 (s, 9H).
<b>Teoc intermediate for 67</b>		2-(Trimethylsilyl)ethyl methyl(3-(3-(1-methyl-5-oxo-1,2,3,5-tetrahydro-4H-pyrido[3,4-e][1,4]diazepin-4-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 8.30 (bs, 2H), 7.54 (d, J = 4.8 Hz, 1H), 7.28-7.24 (m, 2H), 7.05 (br, 1H), 6.98-6.94 (m, 3H), 6.86 (d, J = 8.0 Hz, 1H), 5.46 (bs, 1H), 4.14 (bs, 2H), 3.81-3.79 (m, 2H), 3.51-


			3.38 (m, 4H), 3.00 (s, 3H), 2.90 (s, 3H), 2.33 (bs, 1H), 2.20 (bs, 1H), 0.95 (bs, 2H), 0.04 (s, 9H).
<b>Teoc intermediate for 69</b>		2-(Trimethylsilyl)ethyl methyl(3-(3-(1-methyl-5-oxo-1,2,3,5-tetrahydro-4H-benzo[e][1,4]diazepin-4-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ) δ 7.43-6.70 (m, 11H), 5.46 (bs, 1H), 4.14 (bs, 2H), 3.84-3.74 (m, 4H), 3.46-3.31 (m, 2H), 2.86 (s, 3H), 2.85 (s, 3H), 2.84 (s, 3H), 2.36-2.12 (bs, 2H), 0.97 (bs, 2H), 0.04 (s, 9H).
<b>Teoc intermediate for 71</b>		2-(Trimethylsilyl)ethyl (S)-methyl(3-(3-(4-methyl-7-oxo-1,4-diazepan-1-yl)phenoxy)-3-(thiophen-2-yl)propyl)carbamate	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> ) δ 7.22-7.15 (m, 2H), 7.01 (m, 1H), 6.93-6.91 (m, 1H), 6.78-6.76 (m, 2H), 5.41 (bs, 1H), 4.13 (bs, 2H), 3.77-3.76 (m, 2H), 3.41 (bs, 2H), 2.88 (s, 3H), 2.82-2.81 (m, 2H), 2.68-2.64 (m, 4H), 2.37 (s, 3H), 2.30 (bs, 1H), 2.17 (bs, 1H), 0.93 (bs, 2H), 0.04 (s, 9H).


## HPLC traces of final compounds.


Compound	HPLC chromatogram	Purity (%)																												
15-1	<p>DAD1 B, Sig=254,16 Ref=360,100 (PAULA\PAL-1232BISF102.D)</p> <p>mAU</p> <p>2500 2000 1500 1000 500 0</p> <p>2 4 6 8 10 min</p> <table border="1"> <thead> <tr> <th>Peak #</th> <th>RetTime [min]</th> <th>Type</th> <th>Width [min]</th> <th>Area [mAU*s]</th> <th>Height [mAU]</th> <th>Area %</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>4.628</td> <td>VV</td> <td>0.0507</td> <td>114.84566</td> <td>34.66278</td> <td>1.1075</td> </tr> <tr> <td>2</td> <td>4.832</td> <td>VV</td> <td>0.0775</td> <td>85.88580</td> <td>15.30203</td> <td>0.8283</td> </tr> <tr> <td>3</td> <td>5.038</td> <td>VV</td> <td>0.0577</td> <td>1.01688e4</td> <td>2714.82275</td> <td>98.0642</td> </tr> </tbody> </table>	Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %	1	4.628	VV	0.0507	114.84566	34.66278	1.1075	2	4.832	VV	0.0775	85.88580	15.30203	0.8283	3	5.038	VV	0.0577	1.01688e4	2714.82275	98.0642	98.0
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %																								
1	4.628	VV	0.0507	114.84566	34.66278	1.1075																								
2	4.832	VV	0.0775	85.88580	15.30203	0.8283																								
3	5.038	VV	0.0577	1.01688e4	2714.82275	98.0642																								
16a	<p>DAD1 B, Sig=254,16 Ref=360,100 (PAULA\PAL-1050F200003.D)</p> <p>mAU</p> <p>500 400 300 200 100 0</p> <p>2 4 6 8 10 min</p> <table border="1"> <thead> <tr> <th>Peak #</th> <th>RetTime [min]</th> <th>Type</th> <th>Width [min]</th> <th>Area [mAU*s]</th> <th>Height [mAU]</th> <th>Area %</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>4.747</td> <td>VV</td> <td>0.0556</td> <td>34.72219</td> <td>9.73376</td> <td>1.5998</td> </tr> <tr> <td>2</td> <td>4.886</td> <td>VV</td> <td>0.0539</td> <td>2135.62793</td> <td>624.27246</td> <td>98.4002</td> </tr> </tbody> </table>	Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %	1	4.747	VV	0.0556	34.72219	9.73376	1.5998	2	4.886	VV	0.0539	2135.62793	624.27246	98.4002	98.4							
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %																								
1	4.747	VV	0.0556	34.72219	9.73376	1.5998																								
2	4.886	VV	0.0539	2135.62793	624.27246	98.4002																								
16b	<p>DAD1 B, Sig=254,16 Ref=360,100 (SECUENCIA\JMLV 2013-12-02 17-06-51\ASM-1762E-2.D)</p> <p>mAU</p> <p>1400 1200 1000 800 600 400 200 0</p> <p>2 4 6 8 10 min</p> <table border="1"> <thead> <tr> <th>Peak #</th> <th>RetTime [min]</th> <th>Type</th> <th>Width [min]</th> <th>Area [mAU*s]</th> <th>Height [mAU]</th> <th>Area %</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>4.640</td> <td>BV</td> <td>0.0581</td> <td>47.71693</td> <td>12.61813</td> <td>0.7921</td> </tr> <tr> <td>2</td> <td>4.999</td> <td>VB</td> <td>0.0563</td> <td>5872.99072</td> <td>1618.42480</td> <td>97.4885</td> </tr> <tr> <td>3</td> <td>5.458</td> <td>VV</td> <td>0.0603</td> <td>103.58255</td> <td>25.01776</td> <td>1.7194</td> </tr> </tbody> </table>	Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %	1	4.640	BV	0.0581	47.71693	12.61813	0.7921	2	4.999	VB	0.0563	5872.99072	1618.42480	97.4885	3	5.458	VV	0.0603	103.58255	25.01776	1.7194	97.4
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %																								
1	4.640	BV	0.0581	47.71693	12.61813	0.7921																								
2	4.999	VB	0.0563	5872.99072	1618.42480	97.4885																								
3	5.458	VV	0.0603	103.58255	25.01776	1.7194																								






























## HPLC traces ee determination of final compounds

Compound	HPLC chromatogram	ee (%)																														
31aR	<p>DAD1 C, Sig=235,4 Ref=550,80</p> <p>mAU</p> <p>Time [min]</p> <table border="1"> <thead> <tr> <th>Signal:</th> <th colspan="5">DAD1 C, Sig=235,4 Ref=550,80</th> </tr> <tr> <th>RT [min]</th> <th>Type</th> <th>Width [min]</th> <th>Area</th> <th>Height</th> <th>Area%</th> </tr> </thead> <tbody> <tr> <td>14.737</td> <td>BBA</td> <td>1.3431</td> <td>29355.5703</td> <td>323.9961</td> <td>100.0000</td> </tr> <tr> <td></td> <td></td> <td>Sum</td> <td>29355.5703</td> <td></td> <td></td> </tr> </tbody> </table>	Signal:	DAD1 C, Sig=235,4 Ref=550,80					RT [min]	Type	Width [min]	Area	Height	Area%	14.737	BBA	1.3431	29355.5703	323.9961	100.0000			Sum	29355.5703			100						
Signal:	DAD1 C, Sig=235,4 Ref=550,80																															
RT [min]	Type	Width [min]	Area	Height	Area%																											
14.737	BBA	1.3431	29355.5703	323.9961	100.0000																											
		Sum	29355.5703																													
45cS	<p>DAD1 C, Sig=235,4 Ref=550,80</p> <p>mAU</p> <p>Time [min]</p> <table border="1"> <thead> <tr> <th>Signal:</th> <th colspan="5">DAD1 C, Sig=235,4 Ref=550,80</th> </tr> <tr> <th>RT [min]</th> <th>Type</th> <th>Width [min]</th> <th>Area</th> <th>Height</th> <th>Area%</th> </tr> </thead> <tbody> <tr> <td>10.741</td> <td>BB</td> <td>0.5061</td> <td>136.7411</td> <td>3.2421</td> <td>0.4392</td> </tr> <tr> <td>13.353</td> <td>MM</td> <td>1.1639</td> <td>30995.4453</td> <td>443.8264</td> <td>99.5608</td> </tr> <tr> <td></td> <td></td> <td>Sum</td> <td>31132.1864</td> <td></td> <td></td> </tr> </tbody> </table>	Signal:	DAD1 C, Sig=235,4 Ref=550,80					RT [min]	Type	Width [min]	Area	Height	Area%	10.741	BB	0.5061	136.7411	3.2421	0.4392	13.353	MM	1.1639	30995.4453	443.8264	99.5608			Sum	31132.1864			99.1
Signal:	DAD1 C, Sig=235,4 Ref=550,80																															
RT [min]	Type	Width [min]	Area	Height	Area%																											
10.741	BB	0.5061	136.7411	3.2421	0.4392																											
13.353	MM	1.1639	30995.4453	443.8264	99.5608																											
		Sum	31132.1864																													

59S



100

Signal: DAD1 B, Sig=220,4 Ref=550,80

RT [min]	Type	Width [min]	Area	Height	Area%
17.042	VV R	0.5625	15505.0674	389.4476	100.0000
	Sum		15505.0674		